Apr 23, 2009 - Bristol-Myers Squibb Company and AstraZeneca reported today that the U.S. FDA has determined it needs additional time to complete the review of the New Drug Application for ONGLYZA (saxagliptin) for the treatment of type 2 diabetes.
the details can be read here.
No comments:
Post a Comment